Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP605930.RAvSdc5O_EIv36fHN8N5gwsoEutBC6sVXv1_uZs83RKMY130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP605930.RAvSdc5O_EIv36fHN8N5gwsoEutBC6sVXv1_uZs83RKMY130_assertion type Assertion NP605930.RAvSdc5O_EIv36fHN8N5gwsoEutBC6sVXv1_uZs83RKMY130_head.
- NP605930.RAvSdc5O_EIv36fHN8N5gwsoEutBC6sVXv1_uZs83RKMY130_assertion description "[Clinically, 11q23 patients had acute lymphoblastic leukemia (ALL) more often as their primary disease and a shorter latency from start of treatment for the primary disease to their t-MDS/t-AL diagnosis, except when compared with the inv(16) subgroup.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP605930.RAvSdc5O_EIv36fHN8N5gwsoEutBC6sVXv1_uZs83RKMY130_provenance.
- NP605930.RAvSdc5O_EIv36fHN8N5gwsoEutBC6sVXv1_uZs83RKMY130_assertion evidence source_evidence_literature NP605930.RAvSdc5O_EIv36fHN8N5gwsoEutBC6sVXv1_uZs83RKMY130_provenance.
- NP605930.RAvSdc5O_EIv36fHN8N5gwsoEutBC6sVXv1_uZs83RKMY130_assertion SIO_000772 11921271 NP605930.RAvSdc5O_EIv36fHN8N5gwsoEutBC6sVXv1_uZs83RKMY130_provenance.
- NP605930.RAvSdc5O_EIv36fHN8N5gwsoEutBC6sVXv1_uZs83RKMY130_assertion wasDerivedFrom befree-20150227 NP605930.RAvSdc5O_EIv36fHN8N5gwsoEutBC6sVXv1_uZs83RKMY130_provenance.
- NP605930.RAvSdc5O_EIv36fHN8N5gwsoEutBC6sVXv1_uZs83RKMY130_assertion wasGeneratedBy ECO_0000203 NP605930.RAvSdc5O_EIv36fHN8N5gwsoEutBC6sVXv1_uZs83RKMY130_provenance.